30 closest matches · ranked by relevance
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Lymphoma
Primary: Median Progression-free Survival — 5 months
Cutaneous T-Cell Lymphoma
Primary: Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT) — 16.7; 20.3; 18.5 percentage
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Lymphoma, B-Cell
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Aggressive Non-Hodgkin Lymphoma · Indolent Non-Hodgkin Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma
Primary: Number of Patients That Experienced a Dose Limiting Toxicity (DLT) — 0 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 · Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Overall Response Rate — 6; 2; 8; 1 participants
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Overall Response Rate — 40; 55; 29 percentage of patients
Cutaneous T Cell Lymphoma
Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants
Non-Hodgkin's Lymphoma
Primary: Progression Free Survival — 389; 334 days — p=0.039
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Lymphoma, T-Cell, Cutaneous
Primary: Percentage of Patients With Complete or Partial Response as Measured by Change in Lesion Severity Using CAILS (Composite Assessment of Index Lesion Severity) — 27; 0…
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Lymphoma
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Non-Hodgkin's Lymphoma
Primary: ORR — 88; 81 percentage of patients